CDX Holdings

CDx Diagnostics (CDX Holdings) is a commercial-stage diagnostic company focused on the early detection and prevention of cancer through advanced laboratory testing and artificial intelligence. The company's flagship technology, WATS3D, utilizes a proprietary computer-assisted brush biopsy and 3D imaging AI to identify precancerous cells in the esophagus, specifically targeting Barrett’s Esophagus. By providing more comprehensive sampling than traditional forceps biopsies, CDx Diagnostics aims to improve patient outcomes in gastrointestinal and oral health. The company operates a specialized pathology laboratory to process these samples and provide actionable insights to clinicians. Its products are designed to detect dysplasia at a stage where it can be treated before progressing to invasive cancer.